About Sunbird Bio
Sunbird Bio is a company based in Singapore founded in 2020 by Carine Lim, Nicholas Ho, and Huilin Shao. Sunbird Bio has raised $14 million across 1 funding round from investors including Lilly, EDBI and ClavystBio. Sunbird Bio has completed 1 acquisition, including Glympse Bio. Sunbird Bio offers products and services including APEX Test and ELISA Technology. Sunbird Bio operates in a competitive market with competitors including Guardant Health, Natera, Foundation Medicine, ArcherDX and Strand Life Sciences, among others.
- Headquarter Singapore
- Founders Carine Lim, Nicholas Ho, Huilin Shao
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Sunbird Bio Pte. Ltd.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$14 M (USD)
in 1 rounds
-
Latest Funding Round
$14 M (USD), Series B
Oct 16, 2024
-
Investors
Lilly
& 4 more
-
Employee Count
Not available
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Sunbird Bio
Sunbird Bio offers a comprehensive portfolio of products and services, including APEX Test and ELISA Technology.
Blood test for detecting neurological disorders like Alzheimer's.
Sensor-based system for identifying disease proteins in blood.
People of Sunbird Bio
Unlock access to complete
Unlock access to complete
Funding Insights of Sunbird Bio
Sunbird Bio has successfully raised a total of $14M through 1 strategic funding round. The most recent funding activity was a Series B round of $14 million completed in October 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Sunbird Bio
Sunbird Bio has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Lilly, EDBI and ClavystBio.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government-backed investments are directed toward healthcare, fintech, and various sectors.
|
Locked | Locked | Locked | |
|
US focused venture capital firm
|
Locked | Locked | Locked | |
|
Tech startups are funded by S32, a venture capital entity.
|
Locked | Locked | Locked |
Investor details for Sunbird Bio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Sunbird Bio
Sunbird Bio has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Glympse Bio.
Investment portfolio details for Sunbird Bio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Multiple human diseases are monitored noninvasively through urine-based analysis.
|
Locked | Locked | 2015 | Locked |
Complete acquisition details for Sunbird Bio
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Sunbird Bio
Detailed financials for Sunbird Bio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Sunbird Bio Comparisons
Peer comparison for Sunbird Bio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Sunbird Bio
Sunbird Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, Natera, Foundation Medicine, ArcherDX and Strand Life Sciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Digital sequencing technology for cancer detection is developed.
|
|
| Locked | Locked | Locked |
Developer of cell-free DNA testing for oncology, women’s health, and organ health
|
|
| Locked | Locked | Locked |
Genomics-based diagnostic tests for cancer are provided.
|
|
| Locked | Locked | Locked |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| Locked | Locked | Locked |
Provider of omics-based solutions for clinical genomics, systems biology, and drug discovery
|
|
| Locked | Locked | Locked |
Health risks are identified through online genetic and diagnostic testing.
|
Detailed competitors of Sunbird Bio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Sunbird Bio
Complete news archive for Sunbird Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sunbird Bio
Sunbird Bio was founded in 2020 and raised its 1st funding round 4 years after it was founded.
Sunbird Bio is headquartered in Singapore.
John McDonough is the current CEO of Sunbird Bio.
Sunbird Bio is a funded company, having raised a total of $14M across 1 funding round to date.
Sunbird Bio was founded in 2020 in Singapore within the biotechnology sector. Diagnostic technologies are developed for detecting infectious diseases, cancer biomarkers, and neurological conditions. The enVision Platform is employed for infectious disease identification and cancer detection. The APEX Platform is utilized to identify protein aggregates linked to neurodegenerative diseases. Operations focus on advancing these platforms for medical diagnostics.
Sunbird Bio's top competitors include Guardant Health, Strand Life Sciences and Foundation Medicine.
Sunbird Bio offers APEX Test and ELISA Technology.
Sunbird Bio has made 1 acquisition, including Glympse Bio.
Sunbird Bio has 5 investors. Key investors include Lilly, EDBI, ClavystBio, Polaris Partners, and S32.